RTOG 0518: randomized phase III trial to evaluate zoledronic acid for prevention of osteoporosis and associated fractures in prostate cancer patients

Screening for Osteoporosis in Men: A Clinical Practice Guideline from the American College of Physicians

(2013) Amir Qaseem et al.   ANNALS OF INTERNAL MEDICINE

Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis

(2012) Steven Boonen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis

(2011) A Serpa Neto et al.   PROSTATE CANCER AND PROSTATIC DISEASES

Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer

(2010) Pamela Taxel et al.   BJU INTERNATIONAL

2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary

(2010) A. Papaioannou et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer

(2010) Philip J. Saylor et al.   JOURNAL OF UROLOGY

Osteoporosis and Fractures

(2008) Angela M. Cheung et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK

(2008) J. A. Kanis et al.   OSTEOPOROSIS INTERNATIONAL